Details of the Drug
General Information of Drug (ID: DMO10FD)
Drug Name |
1-(Propan-2-ylidene)thiosemicarbazide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Acetone thiosemicarbazone; 1752-30-3; Thiosemicarbazone acetone; ACETONE THIOSEMICARBAZIDE; Acetone, thiosemicarbazone; Hydrazinecarbothioamide, 2-(1-methylethylidene)-; Acetonthiosemikarbazon; Acetonethiosemicarbazone; 2-(1-Methylethylidene)hydrazinecarbothioamide; NSC 711; Acetonthiosemikarbazon [Czech]; UNII-C3U604L47F; HSDB 6422; EINECS 217-137-9; (isopropylideneamino)thiourea; AI3-22961; CHEMBL500557; (propan-2-ylideneamino)thiourea; C3U604L47F; 2-(propan-2-ylidene)hydrazinecarbothioamide; WLN: SUYZMNUY1& AC1MCI32
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 131.2 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -0.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||